Cost-effectiveness analysis of medical treatment of benign prostatic hyperplasia in the Brazilian public health system

Garraway WM, 1991, High prevalence of benign prostatic hypertrophy in the community, Lancet., 338, 469, 10.1016/0140-6736(91)90543-X

Jacobsen SJ, 1995, New diagnostic and treatment guidelines for benign prostatic hyperplasia: Potential impact in the United States, Arch Intern Med., 155, 477, 10.1001/archinte.1995.00430050053006

Boyle P, 2003, The prevalence of lower urinary tract symptoms in men and women in four centres: The UrEpik study, BJU Int., 92, 409, 10.1046/j.1464-410X.2003.04369.x

Verhamme KM, 2002, Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the Triumph project, Eur Urol., 42, 323, 10.1016/S0302-2838(02)00354-8

Clifford GM, 2000, How do symptoms indicative of BPH progress in real life practice?: The UK experience, Eur Urol., 38, 48, 10.1159/000052401

Logie JW, 2001, Lower urinary tract symptoms suggestive of benign prostatic obstruction-Triumph: the role of general practice databases, Eur Urol., 39, 42, 10.1159/000052567

Wagrell L, 2002, Feedback microwave thermotherapy versus TURP for clinical BPH-a randomized controlled multicenter study, Urology, 60, 292, 10.1016/S0090-4295(02)01740-5

Jacobsen SJ, 1997, Natural history of prostatism: risk factors for acute urinary retention, J Urol., 158, 481, 10.1016/S0022-5347(01)64508-7

2003, Chapter 1: Diagnosis and treatment recommendations, J Urol., 170, 530, 10.1097/01.ju.0000078083.38675.79

McConnell JD, 1998, The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia: Finasteride Long-Term Efficacy and Safety Study Group, N Engl J Med., 338, 557, 10.1056/NEJM199802263380901

McConnell JD, 2003, The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia, N Engl J Med., 2387, 10.1056/NEJMoa030656

Roehrborn CG, 2010, The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study, Eur Urol., 57, 123, 10.1016/j.eururo.2009.09.035

Kaplan S, 2000, Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride, The Pless Study Group. Urology., 56, 610

Tsukamoto T, 2009, Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia, Int J Urol., 16, 745, 10.1111/j.1442-2042.2009.02357.x

Debruyne FM, 1998, Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group, Eur Urol., 34, 169, 10.1159/000019706

Kaplan SA, 2006, Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 mL or greater, J Urol., 175, 217, 10.1016/S0022-5347(05)00041-8

2009

2012

Kristal AR, 2007, Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial, J Urol., 177, 1395, 10.1016/j.juro.2006.11.065

Roehrborn CG, 2005, Acute urinary retention: risks and management, Rev Urol., 7, S31

Crawford ED, 2006, Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo, J Urol., 175, 1422, 10.1016/S0022-5347(05)00708-1

Tacklind J, 2010, 10

Kirby RS, 2003, Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial, Urology, 61, 119, 10.1016/S0090-4295(02)02114-3

Roehrborn CG, 2006, Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study, BJU Int., 97, 734, 10.1111/j.1464-410X.2006.06110.x

Lloyd SN, 1992, Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial, Br J Urol., 70, 17, 10.1111/j.1464-410X.1992.tb15862.x

Boyle P, 2004, 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery, Eur Urol., 45, 620, 10.1016/j.eururo.2003.09.012

Thompson IM, 2003, The influence of finasteride on the development of prostate cancer, N Engl J Med., 17, 349: 215

Kaplan SA, 2009, PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer, Urology, 73, 935, 10.1016/j.urology.2008.09.079

Lucia MS, 2007, Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial, J Natl Cancer Inst., 99, 1375, 10.1093/jnci/djm117